Ragweed, mold, and lingering warm temperatures are driving this year's fall allergic rhinitis season, and clinicians fielding a fresh wave of nasal symptom complaints now have an updated evidence base to prescribe against.1 The Allergic Rhinitis and its Impact on Asthma (ARIA) initiative, in collaboration with the European Academy of Allergy and Clinical Immunology (EAACI), published its 2024-2025 revision of the ARIA guidelines across 2 manuscripts in the journal Allergy earlier this year, with part 1 on intranasal treatments appearing in April 2026 and part 2 on oral and ocular treatments following in June 2026.2,3
